Skip to main content
SupplementScience
Palmitoylethanolamide (PEA) supplement
Endocannabinoid-like Lipid

Palmitoylethanolamide (PEA): Benefits, Dosage, Forms & Research

Endocannabinoid-like Lipid

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

TL;DR — Quick Answer

PEA at 300-1,200mg daily reduces chronic and neuropathic pain by 40-60% in clinical trials. It works through PPAR-alpha activation and mast cell stabilization — not through opioid or cannabinoid receptors. Micronized forms have better absorption. Very safe with no known drug interactions.

Key Facts

What it is
An endogenous fatty acid amide that activates PPAR-alpha and modulates mast cells
Primary benefits
  • Reduces chronic and neuropathic pain 40-60%
  • Activates PPAR-alpha anti-inflammatory pathway
  • Stabilizes mast cells to reduce inflammation
  • No known drug interactions
  • Endogenous compound with excellent safety
Typical dosage
600-1,200mg daily (micronized form preferred)
Evidence level
Moderate
Safety profile
Generally Safe

What the Research Says

PEA was first identified in the 1950s and its analgesic properties were studied by Nobel laureate Rita Levi-Montalcini. A comprehensive 2017 meta-analysis by Paladini et al. (12 RCTs, n=1,188) confirmed significant pain reduction across chronic pain conditions. PEA acts through PPAR-alpha activation (reducing NF-kB-mediated inflammation) and mast cell stabilization (the ALIA mechanism described by Levi-Montalcini). Unlike cannabinoids, PEA does not bind CB1 or CB2 receptors and has no psychoactive effects. It enhances anandamide signaling indirectly via FAAH inhibition. The micronized/ultra-micronized forms are critical for efficacy due to PEA's poor solubility in standard powder form. Its remarkable safety profile — no known drug interactions, no psychoactive effects, no tolerance — makes it uniquely suitable for long-term pain management.

Benefits of Palmitoylethanolamide (PEA)

  • Chronic pain reduction — a 2017 meta-analysis (Paladini et al., 12 RCTs, n=1,188) found PEA significantly reduced pain intensity compared to placebo or standard therapy across multiple chronic pain conditions
  • Neuropathic pain — Hesselink and Hekker (2012) reviewed multiple trials showing PEA 600-1,200mg daily reduced sciatic, diabetic neuropathy, and carpal tunnel pain by 40-60%
  • PPAR-alpha activation — PEA is a direct agonist of peroxisome proliferator-activated receptor alpha, which suppresses NF-kB and reduces pro-inflammatory gene expression
  • Mast cell stabilization — PEA reduces mast cell degranulation and histamine release via the ALIA mechanism (Autacoid Local Inflammation Antagonism), reducing neurogenic inflammation
  • Entourage effect — PEA enhances the activity of endocannabinoid anandamide by inhibiting its degradation enzyme FAAH, amplifying the body's natural pain-modulating system
Did you know?

PEA was first identified in the 1950s and its analgesic properties were studied by Nobel laureate Rita Levi-Montalcini.

Forms of Palmitoylethanolamide (PEA)

FormBioavailabilityBest For
Micronized PEA (um-PEA)HighRecommended form — particle size reduction dramatically improves absorption and clinical efficacy
Ultra-Micronized PEAVery HighMaximum absorption — even smaller particle size; used in most clinical trials
Standard PEA PowderLowNot recommended — poor absorption due to lipophilic nature and large particle size

Dosage Recommendations

General recommendation: 600-1,200mg micronized PEA daily, in 2 divided doses

Timing: Take with meals to enhance absorption of this lipophilic compound; split into 2 daily doses • Take with food for best absorption.

Dosage by Condition

ConditionRecommended DoseEvidence
Chronic pain600mg twice daily (1,200mg/day)Moderate
Neuropathic pain600mg twice daily for 3 weeks, then 600mg once dailyModerate
General anti-inflammatory300-600mg dailyEmerging

Upper limit: Up to 1,200mg/day has been used in clinical trials; no dose-limiting toxicity has been identified

Side Effects and Safety

Safety profile: Generally Safe

Potential Side Effects

  • Very well tolerated — no significant side effects reported in clinical trials at doses up to 1,200mg/day
  • Rare mild GI discomfort
  • No psychoactive effects despite endocannabinoid system modulation
  • No withdrawal effects or tolerance development reported

Drug & Supplement Interactions

  • No known drug interactions — PEA is an endogenous compound with a very clean safety profile
  • May complement analgesics (NSAIDs, acetaminophen, pregabalin) — additive pain relief without adverse interactions
  • Theoretically safe to combine with most medications, but inform your healthcare provider
Check Palmitoylethanolamide (PEA) interactions with other supplements →
BenefitsDosage GuideSide EffectsTypes & FormsResearchFAQ

Related Conditions

Inflammation

Related Supplements

Omega-3 Fish OilTurmeric / CurcuminBoswellia

Frequently Asked Questions

Is PEA a cannabinoid?

No. PEA is classified as an endocannabinoid-like lipid (or ALIAmide). It does not bind CB1 or CB2 cannabinoid receptors and has no psychoactive effects. It enhances the endocannabinoid system indirectly by inhibiting FAAH enzyme, which breaks down anandamide. PEA is legal everywhere and will not cause a positive drug test.

Why is micronized PEA better than regular PEA?

Standard PEA is a lipophilic crystal that dissolves poorly in the GI tract. Micronization reduces particle size to 2-10 micrometers, dramatically increasing surface area and dissolution rate. Clinical trials showing significant pain benefits almost exclusively use micronized or ultra-micronized PEA. Standard PEA powder has very low bioavailability.

How long does PEA take to work for pain?

Some patients notice improvement within 2-3 weeks, but optimal effects typically develop over 4-8 weeks of daily use. A common protocol is 600mg twice daily for 3-4 weeks, then reducing to 600mg once daily for maintenance. PEA builds up gradually in tissues rather than providing immediate pain relief.

References

  1. (). Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician.
  2. (). Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. Journal of Pain Research. DOI
  3. (). The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. British Journal of Pharmacology. DOI